A10BJ02 - search results

Armenia - English - Դեղերի և բժշկական տեխնոլոգիաների փորձագիտական կենտրոնի գործունեության Հայաստանի Հանրապետությունում

victoza solution for s/c injection

novo nordisk a/s - liraglutide - solution for s/c injection - 6mg/ml

victoza solution for s/c injection

novo nordisk a/s - liraglutide - solution for s/c injection - 6mg/ml

Singapore - English - HSA (Health Sciences Authority)

victoza® solution for injection in pre-filled pen 6mgml

novo nordisk pharma (singapore) pte ltd - liraglutide - injection, solution - 6mg/ml - liraglutide 6mg/ml

European Union - English - EMA (European Medicines Agency)

saxenda

novo nordisk a/s - liraglutide - obesity; overweight - drugs used in diabetes - saxenda is indicated as an adjunct to a reduced-calorie diet and increased physical activity for weight management in adult patients with an initial body mass index (bmi) of• ≥ 30 kg/m² (obese), or• ≥ 27 kg/m² to < 30 kg/m² (overweight) in the presence of at least one weight-related comorbidity such as dysglycaemia (pre-diabetes or type 2 diabetes mellitus), hypertension, dyslipidaemia or obstructive sleep apnoea.treatment with saxenda should be discontinued after 12 weeks on the 3.0 mg/day dose if patients have not lost at least 5% of their initial body weight.

European Union - English - EMA (European Medicines Agency)

victoza

novo nordisk a/s - liraglutide - diabetes mellitus, type 2 - drugs used in diabetes - victoza is indicated for the treatment of adults, adolescents and children aged 10 years and above with insufficiently controlled type 2 diabetes mellitus as an adjunct to diet and exerciseas monotherapy when metformin is considered inappropriate due to intolerance or contraindicationsin addition to other medicinal products for the treatment of diabetes.for study results with respect to combinations, effects on glycaemic control and cardiovascular events, and the populations studied.